| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| trc105 | endoglin cd105 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Gestational Trophoblastic Neoplasms[MeSHID:D031901] Liver carcinoma[MeSHID:D006528] Fallopian Tube Carcinoma[MeSHID:D005185] Hemangiosarcoma[MeSHID:D006394] Peritoneum[MeSHID:D010537] Malignant Neoplasms[MeSHID:D009369] Malignant neoplasm of ovary[MeSHID:D010051] Malignant neoplasm of lung[MeSHID:D008175] Sarcoma[MeSHID:D012509] Renal Cell Carcinoma[MeSHID:D002292] Recurrence (disease attribute)[MeSHID:D012008] Age related macular degeneration[MeSHID:D008268] Malignant neoplasm of breast[MeSHID:D001943] Glioblastoma[MeSHID:D005909] |
NA | phase 3 | unknown |
| click here to return to the previous page | ||||||||